Regression of retinal capillary hemangioblastoma with systemic belzutifan in von Hippel-Lindau disease: a case report.

PURPOSE: To report a case of retinal capillary hemangioblastoma (RCH) regression in a patient with von Hippel-Lindau (VHL) disease following treatment with systemic belzutifan.

CASE PRESENTATION: A 49-year-old female with VHL disease presented with a retinal capillary hemangioblastoma in the left eye that had been previously treated with laser therapy. She subsequently developed a new retinal lesion and interval growth of a renal intraparenchymal mass, for which systemic belzutifan was initiated. Four months after treatment initiation, a reduction in the size of the retinal lesions was observed, along with decreased perfusion and vascularity.

CONCLUSION

Systemic belzutifan therapy for VHL disease may induce regression of retinal capillary hemangioblastomas and can be effective as either a primary or an adjunctive treatment modality.